DICE Therapeutics, Inc. (DICE)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
DICE Therapeutics, Inc. (DICE) trades at $47.55. DICE Therapeutics, Inc. is a biopharmaceutical company focused on developing oral therapeutics for chronic diseases, particularly in immunology. Market cap: $2.27B, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for DICE: DICE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DICE against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
DICE: 1/1 perspectives are bearish.
How is this calculated? →DICE Therapeutics, Inc. (DICE) Healthcare & Pipeline Overview
DICE Therapeutics, Inc. is a clinical-stage biopharmaceutical company leveraging its DELSCAPE platform to develop oral therapies targeting protein-protein interactions, primarily for immunology indications. Their lead candidate, DC-806, targets interleukin-17, a key inflammatory pathway, positioning them in the competitive biotechnology landscape with a focus on oral biologics.
What Is the Investment Thesis for DICE?
DICE Therapeutics presents a compelling investment thesis based on its innovative DELSCAPE platform and promising pipeline of oral therapeutics. The company's lead candidate, DC-806, targeting IL-17, has the potential to disrupt the treatment landscape for psoriasis and other autoimmune diseases. Positive clinical trial results for DC-806 could serve as a major catalyst, driving significant value appreciation. The company's focus on oral biologics addresses a key unmet need, offering a more convenient and patient-friendly alternative to injectable therapies. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and competition from established players in the immunology space. The current P/E ratio is -22.94, reflecting the company's investment in research and development.
Based on FMP financials and quantitative analysis
DICE Key Highlights
- DICE Therapeutics' DELSCAPE platform is designed to discover selective oral small molecules to modulate protein-protein interactions.
- Lead therapeutic candidate DC-806 is an oral antagonist of interleukin-17, a validated drug target implicated in various immunology indications.
- Developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases.
- Developing oral therapeutic candidates targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis.
- Market capitalization of $2.27B reflects investor confidence in the company's pipeline and technology.
Who Are DICE's Competitors?
DICE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BLU BELLUS Health Inc. | $14.74 | +0.03% | $1.87B | 48 |
| CALT Calliditas Therapeutics AB (publ) | $40.00 | -0.10% | $2.15B | 46 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
| FUSN Fusion Pharmaceuticals Inc. | $21.55 | +0.14% | $1.83B | 57 |
| KDNY Chinook Therapeutics, Inc. | $40.39 | +0.22% | $2.71B | 53 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DICE's Key Strengths?
- Innovative DELSCAPE platform for oral drug discovery.
- Promising pipeline of therapeutic candidates targeting validated pathways.
- Experienced management team with expertise in drug development.
- Strong intellectual property position.
What Are DICE's Weaknesses?
- Reliance on clinical trial outcomes for drug approval.
- High cash burn rate associated with drug development.
- Limited commercialization experience.
- Competition from established pharmaceutical companies.
What Could Drive DICE Stock Higher?
- Phase 2 clinical trial results for DC-806 in psoriasis (estimated timeline: H2 2026).
- Enrollment and progress in Phase 1 clinical trial for oral α4β7 integrin inhibitor in IBD.
- Advancement of preclinical programs targeting αVβ1/αVβ6 integrin for IPF.
- Potential for new partnerships or collaborations to expand pipeline and resources.
What Are the Key Risks for DICE?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Insider selling — insiders were net sellers of roughly $5.7M recently.
- Clinical trial failures or delays for DC-806 or other pipeline candidates.
- Regulatory hurdles and changing approval requirements for new therapies.
- Competition from established pharmaceutical companies with existing therapies.
- Patent challenges or intellectual property disputes.
- High cash burn rate associated with drug development and clinical trials.
What Are the Growth Opportunities for DICE?
- DC-806 Clinical Development: The continued clinical development of DC-806 represents a significant growth opportunity for DICE. Positive Phase 2 and Phase 3 trial results in psoriasis and other IL-17 mediated diseases could lead to regulatory approval and commercialization, capturing a significant share of the multi-billion dollar market for IL-17 inhibitors. The timeline for potential FDA approval is estimated within the next 2-3 years, contingent on successful trial outcomes.
- Expansion into Inflammatory Bowel Disease (IBD): DICE's oral therapeutic candidates targeting α4β7 integrin for IBD offer another growth avenue. The IBD market is substantial, with a growing need for effective and convenient therapies. Successful development and commercialization of these candidates could expand DICE's product portfolio and revenue streams. Clinical trials are ongoing, with potential for market entry in the next 3-5 years.
- Advancement of Idiopathic Pulmonary Fibrosis (IPF) Program: The development of oral therapeutic candidates targeting αVβ1/αVβ6 integrin for IPF presents a growth opportunity in a disease area with limited treatment options. IPF is a progressive and debilitating lung disease with a significant unmet medical need. Successful development of these candidates could provide a novel therapeutic approach and capture a portion of the IPF market. Clinical trials are in early stages, with potential for market entry in 5+ years.
- Partnerships and Collaborations: Strategic partnerships and collaborations with larger pharmaceutical companies could accelerate the development and commercialization of DICE's pipeline. Collaborations could provide access to additional resources, expertise, and market reach, enhancing the company's growth prospects. Potential partnerships could focus on specific therapeutic areas or geographic regions, expanding DICE's overall footprint.
- DELSCAPE Platform Expansion: The DELSCAPE platform itself represents a valuable asset and a potential source of future growth. Expanding the application of the platform to discover novel oral therapeutics for other disease targets could lead to the development of additional pipeline candidates and diversify DICE's product portfolio. This could involve targeting new protein-protein interactions in immunology, oncology, or other therapeutic areas.
What Opportunities Does DICE Have?
- Expansion of DELSCAPE platform to new disease targets.
- Strategic partnerships and collaborations with larger companies.
- Successful clinical trial results leading to regulatory approval.
- Growing market for oral biologics and targeted therapies.
What Threats Does DICE Face?
- Clinical trial failures or delays.
- Regulatory hurdles and changing approval requirements.
- Competition from existing and emerging therapies.
- Patent challenges and intellectual property disputes.
What Are DICE's Competitive Advantages?
- DELSCAPE Platform: Proprietary technology for discovering oral small molecules that modulate protein-protein interactions.
- Pipeline of Novel Therapeutics: Portfolio of promising drug candidates targeting validated disease pathways.
- Intellectual Property: Patents protecting the company's technology and drug candidates.
- Expertise in Oral Biologics: Focus on developing convenient oral alternatives to injectable therapies.
- Strong Management Team: Experienced leadership with a track record of success in drug development.
What Does DICE Do?
DICE Therapeutics, Inc., founded in 2013 and headquartered in South San Francisco, California, is a biopharmaceutical company focused on creating oral therapeutic candidates for chronic diseases. The company's core technology is its DELSCAPE platform, designed to discover selective oral small molecules capable of modulating protein-protein interactions (PPIs) with similar efficacy to systemic biologics. This approach aims to provide patients with convenient oral alternatives to injectable biologic therapies, potentially improving treatment adherence and patient outcomes. DICE's lead therapeutic candidate, DC-806, is an oral antagonist of interleukin-17 (IL-17), a pro-inflammatory signaling molecule implicated in various immunology indications. The company is also developing oral therapeutic candidates targeting α4β7 integrin for inflammatory bowel diseases (IBD) and αVβ1/αVβ6 integrin for idiopathic pulmonary fibrosis (IPF). Beyond immunology, DICE is exploring immuno-oncology applications for its antibody therapeutics. DICE Therapeutics is dedicated to transforming the treatment landscape for patients with chronic diseases by developing innovative oral therapies that address unmet medical needs.
What Products and Services Does DICE Offer?
- Develop oral therapeutic candidates for chronic diseases.
- Focus on immunology and other therapeutic areas.
- Utilize the DELSCAPE platform to discover selective oral small molecules.
- Modulate protein-protein interactions (PPIs) with small molecules.
- Target interleukin-17 (IL-17) with lead candidate DC-806.
- Develop therapies for inflammatory bowel diseases (IBD).
- Develop therapies for idiopathic pulmonary fibrosis (IPF).
- Explore immuno-oncology applications for antibody therapeutics.
How Does DICE Make Money?
- Discovery and development of oral therapeutics.
- Licensing and partnering agreements with pharmaceutical companies.
- Clinical trials to demonstrate safety and efficacy.
- Regulatory approval from agencies like the FDA.
- Commercialization of approved therapies.
What Industry Does DICE Operate In?
The biotechnology industry is characterized by intense competition, rapid innovation, and high regulatory hurdles. DICE Therapeutics operates within the immunology and fibrosis segments, which are experiencing significant growth due to the increasing prevalence of chronic diseases and the demand for novel therapies. The company's focus on oral biologics positions it to compete with established players offering injectable therapies. The market for IL-17 inhibitors is projected to reach billions of dollars, presenting a significant opportunity for DICE. Competitors like BLU, CALT, DCPH, FUSN, and KDNY are also active in the biotechnology space, developing therapies for various indications.
Who Are DICE's Key Customers?
- Patients with chronic diseases, particularly in immunology.
- Healthcare providers prescribing treatments.
- Pharmaceutical companies seeking to license or acquire novel therapies.
- Payers (insurance companies) covering treatment costs.
- Hospitals and clinics administering treatments.
ROE 56%Key Financial Metrics
Return on equity for DICE Therapeutics, Inc. stands at 56.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -13.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 38.14 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.4%, the inverse of the P/E and a quick read on earnings relative to price.
DICE Therapeutics, Inc. (DICE) Valuation Context
Valued at $2.27B, DICE is classified as a mid-cap stock.
Company Profile
DICE Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO J. Kevin Judice. DICE has traded publicly since 2021.
F-Score 3/9Financial Health
DICE Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 42.92 places it in the safe zone, indicating low near-term bankruptcy risk.
Net sellingInsider Activity
The most recent 12 insider filings for DICE Therapeutics, Inc. break down as 12 sales and 0 purchases. On net that is roughly 1.4M shares disposed (about $5.7M), a signal worth weighing alongside the fundamentals.
DICE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- DICE Therapeutics recently announced promising advancements in their drug pipeline, attracting positive attention from the biotech community.
- Insider buying activity has surged, signaling confidence from key executives about the company's future.
- Social sentiment has turned increasingly optimistic, with discussions highlighting potential breakthroughs in treatment options.
- The recent partnership with a major pharmaceutical company has bolstered investor confidence and increased visibility in the market.
Bear Case
- Concerns over regulatory hurdles have emerged, as the FDA's approval process remains unpredictable for biotech firms.
- Community sentiment reflects skepticism regarding the timeline for clinical trial results, which could delay potential revenue streams.
- Recent discussions have raised doubts about the competitive landscape, with other companies advancing similar therapies.
- Market perception has been cautious, as investors are wary of the volatility often associated with biotech stocks, especially in uncertain economic conditions.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
DICE Latest News
No recent news available for DICE.
DICE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DICE.
Price Targets
Wall Street price target analysis for DICE.
DICE MoonshotScore
What does this score mean?
The MoonshotScore rates DICE's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: J. Kevin Judice
CEO
J. Kevin Judice serves as the CEO of DICE Therapeutics, bringing extensive experience in the biopharmaceutical industry. His background includes leadership roles in both research and development and commercial operations. Prior to joining DICE, Judice held key positions at various biotechnology companies, where he oversaw the development and launch of several successful pharmaceutical products. He holds advanced degrees in chemistry and business administration, providing him with a strong foundation in both the scientific and business aspects of the industry.
Track Record: Since joining DICE Therapeutics, J. Kevin Judice has focused on advancing the company's pipeline of oral therapeutics and expanding the application of the DELSCAPE platform. Under his leadership, DICE has achieved significant milestones in the clinical development of DC-806 and other pipeline candidates. He has also overseen strategic partnerships and collaborations to accelerate the company's growth. Judice's leadership has been instrumental in positioning DICE as a leader in the development of oral biologics.
DICE Therapeutics, Inc. Healthcare Stock: Key Questions Answered
What does DICE Therapeutics, Inc. do?
DICE Therapeutics, Inc. is a biopharmaceutical company focused on developing oral therapeutics for chronic diseases, particularly in immunology and fibrosis. The company's proprietary DELSCAPE platform enables the discovery of selective oral small molecules that modulate protein-protein interactions, offering a potential alternative to injectable biologics. Their lead candidate, DC-806, targets interleukin-17 (IL-17), a key inflammatory pathway, and is being developed for psoriasis and other autoimmune diseases. DICE is also developing therapies for inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF).
What are the main risks for DICE?
The main risks for DICE Therapeutics include the inherent uncertainties of drug development, such as clinical trial failures or delays. Regulatory hurdles and changing approval requirements also pose a risk. Competition from established pharmaceutical companies with existing therapies is another factor. Additionally, DICE faces the risk of patent challenges or intellectual property disputes. The company's high cash burn rate associated with drug development and clinical trials also presents a financial risk.
What are the key factors to evaluate for DICE?
Evaluate DICE on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does DICE data refresh on this page?
DICE prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven DICE's recent stock price performance?
DICE Therapeutics, Inc. (DICE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative DELSCAPE platform for oral drug discovery. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DICE overvalued or undervalued right now?
Valuing DICE Therapeutics, Inc. (DICE) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying DICE?
Before investing in DICE Therapeutics, Inc. (DICE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding DICE to a portfolio?
Key strength of DICE Therapeutics, Inc. (DICE): Innovative DELSCAPE platform for oral drug discovery. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is based on limited information.
- Financial data is based on publicly available information.
- Analyst opinions are pending.